5.08

9.48% 0.44

After Hours: 5.09 0.010 +0.20%

Aardvark Therapeutics Inc (AARD)

Overview News Price History Discussions Forecast

Aardvark Therapeutics Inc stock is traded at $5.08, with a volume of 287.20K. It is up +9.48% in the last 24 hours and down -0.20% over the past month. Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.

Previous Close:

$4.64

Open:

$4.58

24h Volume:

287.20K

Relative Volume:

1.02

Market Cap:

$110.83M

Revenue:

Net Income/Loss:

$-57.59M

P/E Ratio:

-1.918

EPS:

-2.6486

Net Cash Flow:

$-54.27M

1W Performance:

+29.26%

1M Performance:

-0.20%

6M Performance:

-63.53%

1Y Performance:

-36.10%

1-Day Range:

$4.58

$5.1454

1-Week Range:

$3.80

$5.1454

52-Week Range:

$3.35

$17.94

Aardvark Therapeutics Inc Stock (AARD) Company Profile

Name

Aardvark Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(858) 225-7696

Address

4370 LA JOLLA VILLAGE DRIVE, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-03-30

Latest SEC Filings

AARD's Discussions on Twitter

Compare AARD vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AARD Aardvark Therapeutics Inc	5.08	101.23M	0	-57.59M	-54.27M	-2.6486
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Aardvark Therapeutics Inc Stock (AARD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-02-26	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-02-26	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Mar-02-26	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Mar-02-26	Downgrade	Stifel	Buy → Hold
Jan-28-26	Initiated	B. Riley Securities	Buy
Dec-23-25	Initiated	Oppenheimer	Outperform
Dec-12-25	Initiated	William Blair	Outperform
Dec-03-25	Initiated	Raymond James	Strong Buy
Nov-07-25	Initiated	BTIG Research	Buy
Sep-29-25	Initiated	Stifel	Buy
Jun-30-25	Initiated	H.C. Wainwright	Buy
Mar-10-25	Initiated	BofA Securities	Buy
Mar-10-25	Initiated	Cantor Fitzgerald	Overweight
Mar-10-25	Initiated	Morgan Stanley	Overweight
Mar-10-25	Initiated	RBC Capital Mkts	Outperform

View All

Aardvark Therapeutics Inc Stock (AARD) Latest News

Apr 14, 2026

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- Hagens Berman - Finviz

Apr 10, 2026

AARD Forecast, Price Target & Analyst Ratings | AARDVARK THERAPEUTICS INC (NASDAQ:AARD) - ChartMill

Apr 10, 2026

Apr 09, 2026

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate– Hagens Berman - GlobeNewswire Inc.

Apr 09, 2026

Apr 08, 2026